[Acute psychoses and mood disorders in Parkinson disease. Role of antiparkinson therapy].

L-DOPA has progressively replaced atropinic substances in the treatment of the Parkinson's disease but its superiority is not evident in all domains. The same as these substances, it can occasion a secondary psychical pathology essentially presented by affective disorders and psychotic phenomena. The proposed study lays on the comparison between two parkinsonian groups, one undergoing a dopaminergic treatment the other one not. The hallucinary and confusing properties and to a lesser degree the depressive properties of L-DOPA are correlated to risk factors amongst which the average advanced age of the patients has the greatest place.